Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2321]

Safety follow-up of the randomized, phase 3 study DESTINY-Breast03

Dr Erika Hamilton - Sarah Cannon Research Institute, Tennessee, USA

Safety follow-up of the randomized, phase 3 study DESTINY-Breast03 ( Dr Erika Hamilton - Sarah Cannon Research Institute, Tennessee, USA )

Panitumumab plus mFOLFOX6 improves OS for RAS wild-type left sided mCRC

Dr Takayuki Yoshino - National Cancer Center Hospital East, Kashiwa, Japan

Panitumumab plus mFOLFOX6 improves OS for RAS wild-type left sided mCRC ( Dr Takayuki Yoshino - National Cancer Center Hospital East, Kashiwa, Japan )

Comment: Phase III assessment of topotecan, cyclophosphamide and high-dose...

Dr Julie Gralow- Chief Medical Officer, ASCO

$Comment: Phase III assessment of topotecan, cyclophosphamide and high-dose ifosfamide for refractory Ewing sarcoma patients ( Dr Julie Gralow- Chief Medical Officer, ASCO )$

Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast...

Shanu Modi- Memorial Sloan Ketting Cancer Center, Manhattan, USA

Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast cancer patients ( Shanu Modi- Memorial Sloan Ketting Cancer Center, Manhattan, USA )

High-dose ifosfamide standard of care for recurrent and primary refractory...

Dr Martin McCabe - University of Manchester, Manchester, England

$High-dose ifosfamide standard of care for recurrent and primary refractory ewing sarcoma ( Dr Martin McCabe - University of Manchester, Manchester, England )$

Lenalidomide, bortezomib, and dexamethasone ASCT to progress for NDMM: Phase 3...

Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA

Lenalidomide, bortezomib, and dexamethasone ASCT to progress for NDMM: Phase 3 DETERMINATION trial ( Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA )

Single-agent PD-1 blockade as curative-intent treatment in mismatch repair...

Dr Andrea Cercek - Memorial Sloan Kettering Cancer Centre, Manhattan, New York

Single-agent PD-1 blockade as curative-intent treatment in mismatch repair-deficient locally advanced rectal cancer ( Dr Andrea Cercek - Memorial Sloan Kettering Cancer Centre, Manhattan, New York )

Review: Best options in localised prostate cancer

Prof Eleni Efstathiou, Prof Oliver Sartor, Prof Kurt Miller and Prof Karim...

Review: Best options in localised prostate cancer ( Prof Eleni Efstathiou, Prof Oliver Sartor, Prof Kurt Miller and Prof Karim Fizazi )

Ibrutinib improves PFS by 50% for older patients with newly diagnosed mantle...

Dr Michael Wang - MD Anderson Cancer Center, Houston, USA

Ibrutinib improves PFS by 50% for older patients with newly diagnosed mantle cell lymphoma ( Dr Michael Wang - MD Anderson Cancer Center, Houston, USA )

Outcomes of clinico-radiologically advanced cancer (cT4b) of buccal mucosa: A...

Dr Prateek Jain - Tata Medical Center, Kolkata, India

Outcomes of clinico-radiologically advanced cancer (cT4b) of buccal mucosa: A retrospective analysis of 104 patients ( Dr Prateek Jain - Tata Medical Center, Kolkata, India )

COMy 2022: Multiple myeloma roundup

Prof Philippe Moreau - University Hospital of Nantes, Nantes, France

COMy 2022: Multiple myeloma roundup ( Prof Philippe Moreau - University Hospital of Nantes, Nantes, France )

Giving abatacept after checkpoint inhibitors can improve immunotherapy...

Dr Stephen Mok - The University of Texas MD Anderson Cancer Center, Houston, USA

Giving abatacept after checkpoint inhibitors can improve immunotherapy responses in melanoma ( Dr Stephen Mok - The University of Texas MD Anderson Cancer Center, Houston, USA )

More from ecancer